You're always thinking ahead.
We can get behind that.
Valve-in-Valve: the journey starts with the first prosthesis
Watch our EuroPCR symposia if you want to learn more about:
- The impact of valve-in-valve interventions on lifetime management
- Clinical considerations and the procedural technique
- Potential pitfalls and how to mitigate them
- Surgical practice changes in the TAVI era
- Balloon expandable prostheses’ advantage in lifetime management
Speakers
Prof. P. MacCarthy
King’s College Hospital – London, United Kingdom
King’s College Hospital – London, United Kingdom
Prof. Julia Mascherbauer
University Hospital St. Pölten – Lilienfeld, Austria
University Hospital St. Pölten – Lilienfeld, Austria
Prof. Hendrik Treede
University Heart and Vascular Center – Mainz, Germany
University Heart and Vascular Center – Mainz, Germany
Prof. Giuseppe Tarantini
University Hospital of Padua – Padova, Italy
University Hospital of Padua – Padova, Italy
Dr. Radoslaw Parma
Medical University of Silesia – Katowice, Poland
Medical University of Silesia – Katowice, Poland
Prof. Christian Hengstenberg
Medical University of Vienna – Vienna, Austria
Medical University of Vienna – Vienna, Austria
Thinking about the lifetime management of your patients is your Higher Standard.
Preserve future treatment options by choosing SAPIEN 3 Ultra valve first.
Click each to expand
The SAPIEN 3 Ultra valve allows for future coronary intervention with a low frame height and large cell design.
View next topic
SAPIEN 3 Ultra is the only THV approved for aortic valve-in-valve (ViV), aortic THV-in-THV, and mitral valve-in-valve (MViV)*
Treatment options with SAPIEN 3 Platform
*For patients at high or greater surgical risk.
Recommended resources
See all resourcesStay informed with our newsletter
Thank you!
Thank you for signing up to the heartvalves.com newsletter. You will now receive emails on the latest developments and industry insights on heart valve innovation and technology.
References: 1. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13:e008972. DOI: 10.1161/CIRCINTERVENTIONS.120.008972
THV-in-THV = transcatheter heart valve in transcatheter heart valve
PVL = paravalvular leak; TAVI = transcatheter heart valve implantation
PVL = paravalvular leak; TAVI = transcatheter heart valve implantation
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
PP--EU-3363 v1.0